Wave life sciences announces submission of first clinical trial application for wve-006, the first-ever rna editing clinical candidate, and plans for upcoming virtual “r&d day”

Wve-006 is the first-ever rna editing program to enter clinical development and is designed to restore production and circulation of functional, wild-type alpha-1 antitrypsin (aat) protein and reduce levels of mutant z-aat protein, thereby addressing alpha-1 antitrypsin deficiency-related lung disease, liver disease or both
WVE Ratings Summary
WVE Quant Ranking